Emergent BioSolutions Inc.
EBS
$9.12
-$0.11-1.19%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -22.74% | -18.56% | -0.54% | 2.05% | 2.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -22.74% | -18.56% | -0.54% | 2.05% | 2.79% |
| Cost of Revenue | -51.55% | -7.40% | -3.05% | -10.07% | -5.26% |
| Gross Profit | 42.71% | -32.56% | 4.24% | 33.65% | 27.37% |
| SG&A Expenses | -29.56% | -22.77% | -16.26% | -9.23% | -8.71% |
| Depreciation & Amortization | 0.15% | 0.62% | -0.76% | -3.42% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.16% | -14.38% | -9.99% | -0.82% | 2.57% |
| Operating Income | 171.84% | -510.00% | 69.18% | 26.76% | -1.10% |
| Income Before Tax | 132.99% | 88.85% | 80.46% | 76.99% | -7.17% |
| Income Tax Expenses | 475.28% | 919.12% | 62.80% | -2.26% | -85.71% |
| Earnings from Continuing Operations | 123.76% | 76.72% | 74.94% | 73.16% | 2.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 123.76% | 76.72% | 74.94% | 73.16% | 2.44% |
| EBIT | 171.84% | -510.00% | 69.18% | 26.76% | -1.10% |
| EBITDA | 495.99% | -49.92% | 216.63% | 337.80% | -67.89% |
| EPS Basic | 123.23% | 76.89% | 75.68% | 73.83% | 5.90% |
| Normalized Basic EPS | 155.35% | 67.79% | 57.09% | 30.72% | -2.36% |
| EPS Diluted | 121.77% | 75.41% | 74.97% | 73.16% | 5.95% |
| Normalized Diluted EPS | 151.97% | 57.73% | 55.60% | 28.86% | -2.36% |
| Average Basic Shares Outstanding | 3.55% | 3.73% | 3.67% | 3.55% | 3.89% |
| Average Diluted Shares Outstanding | 6.14% | 6.34% | 4.89% | 4.79% | 3.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |